Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 3:2024:4878103.
doi: 10.1155/2024/4878103. eCollection 2024.

Benzoylaconine: Potential Therapeutic Agent for Cardiovascular Diseases From Fuzi

Chenggang Xu  1 , Le Tang  2 , Lixin Hu  3 , Yunzhe Huang  4 , Jin Tang  4 , Xiaohu Wang  3 , Feng Wang  1
Affiliations
Review

Benzoylaconine: Potential Therapeutic Agent for Cardiovascular Diseases From Fuzi

Chenggang Xu et al. Cardiovasc Ther. .

Abstract

Modern pharmacological studies have elucidated the presence of aconitine (AC) alkaloids, polysaccharides, and saponins as the primary bioactive constituents of Fuzi. Among these, benzoylaconine, a pivotal active compound, demonstrates notable pharmacological properties including antitumor, anti-inflammatory, and cardiovascular protective effects. In recent years, benzoylaconine has garnered significant attention in basic research on heart diseases, emerging as a focal point of investigation. This paper presents a comprehensive review of the pharmacological effects of benzoylaconine, alongside an overview of advancements in metabolic characterization. The objective is to furnish valuable insights that can serve as a cornerstone for further exploration, utilization, and advancement of benzoylaconine in pharmacological research.

Keywords: anti-inflammation; benzoylaconine; cardiac diseases; pharmacokinetics; pharmacological effects.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Relationships between the studied MDAs and DDAs of Fuzi.
Figure 2
Figure 2
Mechanism of action of BAC on cardiovascular diseases.
Figure 3
Figure 3
Main anti-inflammatory mechanisms of action of BAC.
Figure 4
Figure 4
Major metabolites of benzoylaconitine.
See this image and copyright information in PMC

References

    1. Committee for the pharmacopoeia of China. Pharmacopoeia of China, Part I . Beijing: China Medical Science and Technology Press; 2020.
    1. Zhou G., Tang L., Zhou X., Wang T., Kou Z., Wang Z. A review on phytochemistry and pharmacological activities of the processed lateral root of Aconitum carmichaelii Debeaux. Journal of Ethnopharmacology . 2015;160:173–193. doi: 10.1016/j.jep.2014.11.043. - DOI - PubMed
    1. Zhang Z., Yang S., Lin X., et al. Metabolomics of Spleen-Yang deficiency syndrome and the therapeutic effect of Fuzi Lizhong pill on regulating endogenous metabolism. Journal of Ethnopharmacology . 2021;278, article 114281 doi: 10.1016/j.jep.2021.114281. - DOI - PubMed
    1. Park J., Bak S., Chu H., et al. Current research status and implication for further study of real-world data on East Asian traditional medicine for heart failure: a scoping review. Healthcare . 2024;12(1) doi: 10.3390/healthcare12010061. - DOI - PMC - PubMed
    1. Liu X., Xie X., Luo M., et al. The synergistic compatibility mechanisms of fuzi against chronic heart failure in animals: a systematic review and meta-analysis. Frontiers in Pharmacology . 2022;13, article 954253 doi: 10.3389/fphar.2022.954253. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources